These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38301349)

  • 21. Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries.
    Mease PJ; Liu M; Rebello S; Kang H; Yi E; Park Y; Greenberg JD
    Rheumatol Ther; 2019 Dec; 6(4):529-542. PubMed ID: 31529278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Blachley T; Dube B; McLean RR; Kim N; Hur P; Ogdie A
    J Rheumatol; 2022 Jul; 49(7):700-706. PubMed ID: 35428716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
    Ørnbjerg LM; Brahe CH; Askling J; Ciurea A; Mann H; Onen F; Kristianslund EK; Nordström D; Santos MJ; Codreanu C; Gómez-Reino J; Rotar Z; Gudbjornsson B; Di Giuseppe D; Nissen MJ; Pavelka K; Birlik M; Kvien T; Eklund KK; Barcelos A; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Loft AG; van der Horst-Bruinsma I; Jones G; Iannone F; Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
    Ann Rheum Dis; 2019 Nov; 78(11):1536-1544. PubMed ID: 31431486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.
    Fornaro M; Righetti G; Abbruzzese A; Lopalco G; Cacciapaglia F; Anelli MG; Venerito V; Iannone F
    Clin Rheumatol; 2021 Sep; 40(9):3659-3665. PubMed ID: 33864158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
    Athanassiou P; Psaltis D; Georgiadis A; Katsifis G; Theodoridou A; Gazi S; Sidiropoulos P; Tektonidou MG; Bounas A; Kandyli A; Vounotrypidis P; Sakellariou GT; Vassilopoulos D; Huang Z; Petrikkou E; Boumpas D
    Rheumatol Int; 2023 Oct; 43(10):1871-1883. PubMed ID: 37402886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment Patterns and Healthcare Resource Utilization Among Newly Diagnosed Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, and Hidradenitis Suppurativa Patients with Past Diagnosis of an Inflammatory Condition: A Retrospective Cohort Analysis of Claims Data in the United States.
    Hopson S; Gibbs LR; Syed S; Low R; McClung L; Beaty S
    Adv Ther; 2023 Oct; 40(10):4358-4376. PubMed ID: 37486558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the 'GO-UP' study.
    Athanassiou P; Kotrotsios A; Kallitsakis I; Bounas A; Dimitroulas T; Garyfallos A; Tektonidou MG; Vosvotekas G; Livieratos A; Petrikkou E; Katsifis G
    Qual Life Res; 2022 May; 31(5):1385-1399. PubMed ID: 34839451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry.
    Ciurea A; Götschi A; Kissling S; Bernatschek A; Bürki K; Exer P; Nissen MJ; Möller B; Scherer A; Micheroli R
    RMD Open; 2023 Jun; 9(2):. PubMed ID: 37277211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is the C-reactive protein-to-albumin ratio the most remarkable simple inflammatory marker showing active disease in patients with axial spondyloarthritis, psoriatic arthritis, and rheumatoid arthritis?
    Kaplan H; Cengiz G; Şaş S; Eldemir YÖ
    Clin Rheumatol; 2023 Nov; 42(11):2959-2969. PubMed ID: 37470884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort.
    Reich A; Weiß A; Lindner L; Baraliakos X; Poddubnyy D; Zinke S; Stille C; Strangfeld A; Regierer AC
    Arthritis Res Ther; 2023 Aug; 25(1):136. PubMed ID: 37533077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study.
    Currado D; Saracino F; Ruscitti P; Marino A; Pantano I; Vomero M; Berardicurti O; Pavlych V; Di Vico C; Caso F; Costa L; Tasso M; Camarda F; Misceo F; De Vincenzo F; Corrado A; Arcarese L; Rigon A; Vadacca M; Corberi E; Kun L; Trunfio F; Pilato A; Lamberti L; Cantatore FP; Perosa F; Guggino G; Scarpa R; Cipriani P; Ciccia F; Giacomelli R; Navarini L
    Arthritis Res Ther; 2024 Sep; 26(1):162. PubMed ID: 39294672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Schjødt Jørgensen T; Gudbjornsson B; Lederballe Grøn K; Aarrestad Provan S; Michelsen B; Lund Hetland M; Wallman JK; Nordström D; Trokovic N; Love TJ; Krogh NS; Askling J; Jacobsson LTH; Kristensen LE
    Rheumatology (Oxford); 2021 Aug; 60(8):3635-3645. PubMed ID: 33367900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study.
    Alonso S; Villa I; Fernández S; Martín JL; Charca L; Pino M; Riancho L; Morante I; Santos M; Brandy A; Aurrecoechea E; Carmona L; Queiro R
    Front Med (Lausanne); 2021; 8():679009. PubMed ID: 34124110
    [No Abstract]   [Full Text] [Related]  

  • 34. Discordance of Global Assessments by Patient and Physician Is Higher in Female than in Male Patients Regardless of the Physician's Sex: Data on Patients with Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis from the DANBIO Registry.
    Lindström Egholm C; Krogh NS; Pincus T; Dreyer L; Ellingsen T; Glintborg B; Kowalski MR; Lorenzen T; Madsen OR; Nordin H; Rasmussen C; Hetland ML
    J Rheumatol; 2015 Oct; 42(10):1781-5. PubMed ID: 26233511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studie.
    Govoni M; Batalov A; Boumpas DT; D'Angelo S; De Keyser F; Flipo RM; Kellner H; Leroi H; Khalifa A
    Clin Exp Rheumatol; 2024 Mar; 42(3):642-650. PubMed ID: 37976120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study.
    Ortolan A; Lorenzin M; Leo G; Pampaloni F; Messina F; Doria A; Piaserico S; Ramonda R
    Dermatology; 2022; 238(5):897-903. PubMed ID: 35263743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raftlin - a potential biomarker for axial spondyloarthritis and psoriatic arthritis: An observational study.
    Yurdakul OV; Kara M; Ince B; Yildiz C; Yildiz T; Kilicoglu MS; Aydin T; Ozer OF
    Medicine (Baltimore); 2024 Jun; 103(26):e38770. PubMed ID: 38941376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials.
    Kavanaugh A; Baraliakos X; Gao S; Chen W; Sweet K; Chakravarty SD; Song Q; Shawi M; Rahman P
    Adv Ther; 2023 May; 40(5):2439-2456. PubMed ID: 36995469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis.
    Armağan B; Kılıç L; Farisoğulları B; Yardımcı GK; Bilgin E; Bölek EÇ; Karadağ Ö; Bilgen ŞA; Kiraz S; Ertenli İ; Kalyoncu U
    Rheumatol Int; 2023 Jan; 43(1):147-156. PubMed ID: 36129541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry.
    Moreno-Ramos MJ; Sanchez-Piedra C; Martínez-González O; Rodríguez-Lozano C; Pérez-Garcia C; Freire M; Campos C; Cáliz-Caliz R; Calvo J; Blanco-Madrigal JM; Pérez-Gómez A; Moreno-Martínez MJ; Linares L; Sánchez-Alonso F; Sastré C; Castrejón I
    Rheumatol Ther; 2022 Aug; 9(4):1031-1047. PubMed ID: 35467242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.